About Verge Genomics
Verge Genomics develops drugs for neurodegenerative diseases using computational genomics. Its platform utilizes machine learning to develop therapeutics, specifically for neurological diseases. It analyzes datasets of any size to identify new targets and predict effective drugs. It was founded in 2015 and is based in South San Francisco, California.
Research containing Verge Genomics
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Verge Genomics in 3 CB Insights research briefs, most recently on Dec 12, 2022.
Expert Collections containing Verge Genomics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Verge Genomics is included in 2 Expert Collections, including Digital Health.
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Drug Discovery Tech Market Map
This CB Insights Tech Market Map highlights 220 drug discovery companies that are addressing 12 distinct technology priorities that pharmaceutical companies face.
Latest Verge Genomics News
Jan 9, 2024
Verge Genomics VRG50635, a small molecule PIKfyve inhibitor, is one of the first drugs to enter clinical trials that was entirely discovered and developed using an AI-enabled platform Verge’s proof-of-concept study uses first-of-its-kind, cutting-edge design and technology to deliver more precise and comprehensive insights into how VRG50635 may benefit individuals with ALS “I applaud Verge for creating a bold proof-of-concept design that incorporates cutting-edge technology and scientific innovation in their efforts to create groundbreaking therapies for ALS.” - Dr. Angela Genge, Director, ALS Centre of Excellence for Research and Patient Care, Montreal Neurological Institute-Hospital SOUTH SAN FRANCISCO, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Verge Genomics, a clinical-stage biotechnology company transforming drug discovery and development using artificial intelligence (AI) and human data, today announced the initiation of its Phase 1b proof-of-concept study of VRG50635 for the treatment of sporadic and familial forms of amyotrophic lateral sclerosis (ALS). The study will assess the safety and tolerability of escalating doses of VRG50635, a potential best-in-class, small molecule inhibitor of PIKfyve, a therapeutic target for ALS discovered in diseased human tissues using CONVERGE®, the company’s all-in-human, AI-powered platform. VRG50635 is one of the first drugs to enter the clinic that was entirely discovered and developed from an AI-enabled platform. In traditional ALS clinical trials, a patient's progress is measured in a clinical setting using poorly responsive physician rating scales, which typically provide sparse data to establish proof of concept early in clinical development. In contrast, Verge's study harnesses the power of digital devices to collect thousands of objective, quantitative, relevant measurements directly from the patient, including mobility, breathing, and sleeping all from the comfort of their home. This level of patient data greatly increases the ability to detect disease progression and treatment-related changes, allowing to personalize the assessment of change for each study participant as he/she moves from no treatment to increasingly higher doses of VRG50635, and for longer treatment periods. “Incorporating cutting-edge technology into our ALS proof-of-concept study is a necessity born from the urgent unmet need to efficiently study promising therapeutics for people battling this devastating disease. Our approach and the technology we are incorporating into the VRG50635 proof-of-concept study will make it possible to collect dense amounts of unbiased, objective disease-relevant data to properly assess the safety, tolerability, and potential efficacy, including dose-response, early in clinical development,” said Diego Cadavid, M.D., FAAN, FANA, Chief Medical Officer at Verge Genomics. “Initiating our proof-of-concept study marks another important milestone for Verge and further demonstrates that by leveraging our AI-enabled platform in combination with patient data using a novel study design we are able to more efficiently discover and develop potential drugs for deadly diseases like ALS,” said Alice Zhang, CEO and co-founder of Verge Genomics. “We are tremendously excited by the potentially transformative power of our CONVERGE® platform in redefining the landscape and expediting the journey from lab bench to patients and improving lives worldwide." “I applaud Verge for creating a bold proof-of-concept design that incorporates cutting-edge technology and scientific innovation in their efforts to create groundbreaking therapies for ALS,” said Dr. Angela Genge, Director, ALS Centre of Excellence for Research and Patient Care, Montreal Neurological Institute-Hospital. About VRG50635 VRG50635 is a potent, orally bioavailable PIKfyve inhibitor that improves survival in amyotrophic lateral sclerosis (ALS) patient neurons and has shown efficacy in multiple preclinical studies in ALS-relevant models of motor neuron degeneration. VRG50635 is the only PIKfyve inhibitor in clinical development that has been specifically optimized for the treatment of central nervous system disorders like ALS, with the potential to become a best-in-class therapy. About Amyotrophic Lateral Sclerosis (ALS) ALS, also known as Lou Gehrig’s disease, is a progressive neurodegenerative disease that affects motor neuron cells in the brain and spinal cord causing progressive paralysis of voluntary muscles. ALS often strikes people between the ages of 40 and 70, and it is estimated that 100,000 people worldwide may have the disease at any given time. ALS is fatal and there is currently no cure, and available therapies have only modest benefits for the majority of affected patients, who often succumb to the disease within 2 to 5 years after diagnosis. About Verge Genomics Verge is focused on developing therapeutics for complex diseases with high unmet need, using human genomics from patient disease tissues and machine learning. Verge has created a proprietary all-in-human CONVERGE® platform, featuring one of the field’s largest and most comprehensive databases of multi-omic patient data. The company is led by experienced computational biologists and drug developers who are successfully advancing clinical and preclinical therapeutic programs in various diseases, including ALS and Parkinson’s disease. For additional information, please visit https://www.vergegenomics.com/ and follow us on LinkedIn and Twitter/X . Media Contact:
Verge Genomics Frequently Asked Questions (FAQ)
When was Verge Genomics founded?
Verge Genomics was founded in 2015.
Where is Verge Genomics's headquarters?
Verge Genomics's headquarters is located at 131 Oyster Point Blvd #300, South San Francisco.
What is Verge Genomics's latest funding round?
Verge Genomics's latest funding round is Corporate Minority.
How much did Verge Genomics raise?
Verge Genomics raised a total of $158.12M.
Who are the investors of Verge Genomics?
Investors of Verge Genomics include Alexion, AstraZeneca Rare Disease, ALS Investment Fund, Threshold Ventures, Alumni Ventures, Tao Capital Partners and 19 more.
Who are Verge Genomics's competitors?
Competitors of Verge Genomics include Terray Therapeutics and 2 more.
Compare Verge Genomics to Competitors
Atomwise develops machine learning-based discovery engines and uses deep learning and artificial intelligence (AI)-based neural networks to help discover new medicines. It predicts drug candidates for pharmaceutical companies, start-ups, and research institutions and designs drugs using computational drug design. The company was founded in 2012 and is based in San Francisco, California.
Insitro focuses on drug discovery and development. The company's main services involve the use of machine learning and high-throughput biology to predict successful paths for medicine creation. It aims to avoid costly failures in pharmaceutical research and development (R&D). Insitro primarily sells to the healthcare industry. It was founded in 2018 and is based in South San Francisco, California.
NuMedii develops compounds that modulate diverse networks involved in diseases and can help with myriad aspects of drug discovery including identifying patient subgroups, new therapeutic options, and biomarkers. It assists in discovering connections between drugs and diseases at a systems level. The company was founded in 2008 and is based in Menlo Park, California.
BioLizard is a bioinformatics and data management consulting company operating in the life sciences industry. The company provides tailored solutions such as biomedical data analysis, data mining, pipeline development, machine learning, artificial intelligence, and software engineering. BioLizard primarily serves biotech, pharmaceutical and diagnostic companies, research institutions, and also has experience in the animal health field and food and agriculture R&D. It is based in Ghent, Belgium.
Diverse Biotech is a clinical-stage biopharmaceutical research company that is committed to discovering and developing therapeutics from its proprietary and patented cannabinoid formulations and cancer research. The Company's formulas are discoveries for improving the health and well-being of cancer patients.
Delta4 is a biotech company focused on AI-powered drug discovery for complex and rare diseases. The company offers a platform called Hyper-C, which uses artificial intelligence to discover new indications for drugs with known safety profiles by analyzing drug models against disease profiles. Delta4 primarily serves the biotechnology and pharmaceutical industries by providing innovative solutions for drug indication expansion and streamlining the drug development process. It was founded in 2019 and is based in Vienna, Austria.